ReNetX Bio is expanding its Scientific Advisory Board with key opinion leaders specializing in spinal cord injury.

Andrew Blight, PhD, brings experience as the former Chief Scientific Officer of Acorda Therapeutics.

Daniel P. Lammertse, MD, served as Medical Director of Research at Craig Hospital in Englewood, Colorado and is Professor of Physical Medicine and Rehabilitation at the University of Colorado School of Medicine.

ReNetX Bio is developing first-in-class therapeutics to treat injury and damage to the central nervous system in conditions such as spinal cord injury, stroke, and glaucoma. The company was founded based on innovative technology from Dr. Stephen Strittmatter’s work at Yale University.